Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Atypical or second-generation antipsychotic indicated for the treatment of schizophrenia and other psychotic disorders. Oral administration once daily.
Since the last update, we have not found any published data on its excretion in breastmilk.
Its high percentage of protein binding make it highly unlikely that significant quantities will pass into breast milk.
Cariprazine and its two active metabolites have a very long half-life (2 days, 3 weeks), which could favor the passage into breast milk.
Cariprazine produces minimal effects on prolactin levels. (Culpepper 2022)
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives are preferable (Wichniak 2021), especially during the neonatal period and in cases of prematurity.
See below the information of this related product: